GGrantIndex
← Leaderboards

Eric J Brown

University Of Pennsylvania

$8,645,404
Attributed
$10,811,144
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY200625
$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,811,144 · 8

By mechanism

R01$8,514,575 · 6
R44$1,996,571 · 1
R41$299,998 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsDna BiosynthesisMolecularPreventDna DamageDna Double Strand BreakResponseGenomicsDna Replication ForkBaseGenomeTp53 GeneMediatingAffectPathway InteractionsLeadSignal TransductionMaintenancePhosphotransferasesMalignant NeoplasmsGenerationsGeneticResearch StudyMammalian Cell

Grant awards (28)

Developing biomarkers of response for a new therapy in ovarian cancer$676,860
R01 · FY2025 · CA
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment$347,378
R01 · FY2025 · CA · contact PI
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$1,134,366
R44 · FY2024 · CA
Developing biomarkers of response for a new therapy in ovarian cancer$692,527
R01 · FY2024 · CA
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment$440,628
R01 · FY2024 · CA · contact PI
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$862,205
R44 · FY2023 · CA
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment$461,391
R01 · FY2023 · CA · contact PI
A novel protein quality control system and its role in tumorigenesis$453,169
R01 · FY2021 · CA · contact PI
Role of Daxx in protein folding and tumorigenesis$371,719
R01 · FY2021 · CA · contact PI
Effects of ATR-CHK1 inhibition on genome stability and cancer progression$313,494
R01 · FY2019 · CA · contact PI
Effects of ATR-CHK1 inhibition on genome stability and cancer progression$323,192
R01 · FY2018 · CA · contact PI
Effects of ATR-CHK1 inhibition on genome stability and cancer progression$399,329
R01 · FY2017 · CA · contact PI
Effects of ATR-CHK1 inhibition on genome stability and cancer progression$399,329
R01 · FY2016 · CA · contact PI
Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers$299,998
R41 · FY2016 · CA · contact PI
Effects of ATR-CHK1 inhibition on genome stability and cancer progression$397,683
R01 · FY2015 · CA · contact PI
The role of ATR in preventing age-related diseases$318,160
R01 · FY2015 · AG · contact PI
The role of ATR in preventing age-related diseases$328,000
R01 · FY2014 · AG · contact PI
The role of ATR in preventing age-related diseases$309,960
R01 · FY2013 · AG · contact PI
The role of ATR in preventing age-related diseases$328,000
R01 · FY2012 · AG · contact PI
The role of ATR in preventing age-related diseases$40,000
R01 · FY2012 · AG · contact PI
The role of ATR in preventing age-related diseases$328,000
R01 · FY2011 · AG · contact PI
The role of ATR in preventing age-related diseases$266,715
R01 · FY2010 · AG · contact PI
The role of ATR in preventing age-related diseases$308,971
R01 · FY2009 · AG · contact PI
The role of ATR in preventing age-related diseases$130,836
R01 · FY2009 · AG · contact PI
The role of ATR in preventing age-related diseases$269,777
R01 · FY2008 · AG · contact PI
The role of ATR in preventing age-related diseases$39,375
R01 · FY2008 · AG · contact PI
The role of ATR in preventing age-related diseases$280,384
R01 · FY2007 · AG · contact PI
The role of ATR in preventing age-related diseases$289,698
R01 · FY2006 · AG · contact PI